The impending medical revolution in\ud haemophilia care: one patient’s view

Article English OPEN
Jones, Adam (2015)

The history of haemophilia care has been fraught with extreme successes and epic failures. The development of plasma-derived concentrates made prophylactic treatment and home care possible, but the unintended consequences were devastating for a generation and only abated with the emergence of recombinant products. Now with the arrival of longer-acting factor concentrates and the potential offered by gene therapy, further improvements in medical and social outcomes are possible. But these new treatment approaches raise challenging ethical and moral issues that society must be prepared to confront.
  • References (15)
    15 references, page 1 of 2

    1. Biggs R, Douglas AS, Macfarlane RC, et al. Christmas Disease. BMJ 1952; 2: 1378. doi:

    2. Darby SC, Ewart DW, Giangrande PF, et al. Mortality before and after HIV infection in the complete UK population of haemophiliacs. Nature 1995; 377: 79Q82. doi:10.1038/377079a0

    3. Department of Health. Government response to Lord Archer's Independent report on NHS supplied contaminated blood and blood products. London: Stationary Office; 20 May 2009

    4. Hütter G, Nowak D, Mossner M, et al. LongQterm control of HIV by CCR5 Delta32/Delta32 stemQcell transplantation. N Engl J Med 2009; 360R7S: 692Q8. doi: 10.1056/NEJMoa0802905.

    5. Roth DA, Kessler CM, Pasi KJ, et al; Recombinant Factor IX Study Group. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasmaQderived factor IX concentrates. Blood 2001; 98R13S: 3600Q6.

    6. Zaman SM, Hill FG, Palmer B, Millar CM, Bone A, Molesworth AM, et al. The risk of variant CreutzfeldtQJakob disease among UK patients with bleeding disorders, known to have received potentially contaminated plasma products. Haemophilia. 2011; 17R6S: 931Q7. doi: 10.1111/j.1365Q2516.2011.02508.x.

    7. Miguelino MG, Powell JS. Clinical utility and patient perspectives on the use of extended halfQlife rFIXFc in the management of hemophilia B. Patient Prefer Adherence 2014; 8: 1073Q83. doi: 10.2147/PPA.S54951.

    8. United States of America Food and Drug Administration. FDA approves first longQ acting recombinant coagulation Factor IX concentrate for patients with Hemophilia B. TOnlineU Available from: URL RLast accessed 12/12/2014S.

    9. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006; 12: RSuppl. 3S, 117V121.

    10. Cancio MI, Reiss UM, Nathwani AC, et al. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet 2013; 6: 91Q101. doi: 10.2147/TACG.S31928.

  • Metrics
    views in OpenAIRE
    views in local repository
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    Sunderland University Institutional Repository - IRUS-UK 0 39
Share - Bookmark